Literature DB >> 17567627

How should DSM-V criteria for schizophrenia include cognitive impairment?

Richard S E Keefe1, Wayne S Fenton.   

Abstract

Neurocognitive impairment is considered a core component of schizophrenia and is increasingly under investigation as a potential treatment target. On average, cognitive impairment is severe to moderately severe compared with healthy controls, and almost all patients with schizophrenia demonstrate cognitive decrements compared with their expected level if they had not developed the illness. Compared with patients with affective disorders, cognitive impairment in schizophrenia appears earlier, is more severe, and tends to be more independent of clinical symptoms. While the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, description of schizophrenia includes several references to cognitive impairment, neither the diagnostic criteria nor the subtypology of schizophrenia include a requirement of cognitive impairment. We forward for consideration a proposal that the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria include a specific criterion of "a level of cognitive functioning suggesting a consistent severe impairment and/or a significant decline from premorbid levels considering the patient's educational, familial, and socioeconomic background." The inclusion of this criterion may increase the "point of rarity" with affective psychoses and may increase clinicians' awareness of cognitive impairment, potentially leading to more accurate prognosis and better treatment outcomes. Future research will need to address the validity of these possibilities. The reliable determination of cognitive impairment as part of a standard diagnostic evaluation may present challenges to diagnosticians with limited resources or insufficient expertise. Various cognitive assessment methods for clinicians, including brief assessments and interview-based assessments, are discussed. Given the current emphasis on the development of cognitive treatments, the evaluation of cognition in schizophrenia is an essential component of mental health education.

Entities:  

Mesh:

Year:  2007        PMID: 17567627      PMCID: PMC2632322          DOI: 10.1093/schbul/sbm046

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  41 in total

1.  Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study.

Authors:  J Addington; D Addington
Journal:  Schizophr Res       Date:  2000-07-07       Impact factor: 4.939

2.  Medicine. What are the right targets for psychopharmacology?

Authors:  Steven E Hyman; Wayne S Fenton
Journal:  Science       Date:  2003-01-17       Impact factor: 47.728

3.  Values and assumptions in the development of DSM-III and DSM-III-R: an insider's perspective and a belated response to Sadler, Hulgus, and Agich's "On values in recent American psychiatric classification".

Authors:  R L Spitzer
Journal:  J Nerv Ment Dis       Date:  2001-06       Impact factor: 2.254

4.  Longitudinal study of symptoms and cognitive function in chronic schizophrenia.

Authors:  Catherine Hughes; Veena Kumari; William Soni; Mrigendra Das; Brendon Binneman; Sonia Drozd; Shaun O'Neil; Vallakalil Mathew; Tonmoy Sharma
Journal:  Schizophr Res       Date:  2003-02-01       Impact factor: 4.939

5.  Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates.

Authors:  R M Bilder; R S Goldman; D Robinson; G Reiter; L Bell; J A Bates; E Pappadopulos; D F Willson; J M Alvir; M G Woerner; S Geisler; J M Kane; J A Lieberman
Journal:  Am J Psychiatry       Date:  2000-04       Impact factor: 18.112

6.  Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort.

Authors:  Mary Cannon; Avshalom Caspi; Terrie E Moffitt; HonaLee Harrington; Alan Taylor; Robin M Murray; Richie Poulton
Journal:  Arch Gen Psychiatry       Date:  2002-05

7.  The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia.

Authors:  P D Harvey; M R Serper; L White; M J Parrella; S R McGurk; P J Moriarty; C Bowie; N Vadhan; J Friedman; K L Davis
Journal:  Compr Psychiatry       Date:  2001 Jul-Aug       Impact factor: 3.735

8.  Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. A preliminary study.

Authors:  W G van Gorp; L Altshuler; D C Theberge; J Wilkins; W Dixon
Journal:  Arch Gen Psychiatry       Date:  1998-01

9.  Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance.

Authors:  Rebecca Fuller; Peg Nopoulos; Stephan Arndt; Dan O'Leary; Beng-Choon Ho; Nancy C Andreasen
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

10.  Distinguishing between the validity and utility of psychiatric diagnoses.

Authors:  Robert Kendell; Assen Jablensky
Journal:  Am J Psychiatry       Date:  2003-01       Impact factor: 18.112

View more
  96 in total

1.  Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features.

Authors:  Allison A Curley; Dominique Arion; David W Volk; Josephine K Asafu-Adjei; Allan R Sampson; Kenneth N Fish; David A Lewis
Journal:  Am J Psychiatry       Date:  2011-06-01       Impact factor: 18.112

2.  General and specific functional connectivity disturbances in first-episode schizophrenia during cognitive control performance.

Authors:  Alex Fornito; Jong Yoon; Andrew Zalesky; Edward T Bullmore; Cameron S Carter
Journal:  Biol Psychiatry       Date:  2011-04-22       Impact factor: 13.382

3.  Nitric oxide synthase mediates the ability of darbepoetin alpha to improve the cognitive performance of STOP null mice.

Authors:  Kosuke Kajitani; Michael Thorne; Michel Samson; George S Robertson
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

4.  Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★.

Authors:  Junchao Huang; Yu Zhu; Fengmei Fan; Song Chen; Yuan Hong; Yimin Cui; Xingguang Luo; Shuping Tan; Zhiren Wang; Lan Shang; Ying Yuan; Jianxin Zhang; Fude Yang; Chiang-Shan R Li; Laura M Rowland; Peter Kochunov; Fengyu Zhang; L Elliot Hong; Yunlong Tan
Journal:  Psychiatry Res Neuroimaging       Date:  2020-02-04       Impact factor: 2.376

5.  The involvement of Type II Neuregulin-1 in rat visuospatial learning and memory.

Authors:  Adam R Taylor; Sara B Taylor; James I Koenig
Journal:  Neurosci Lett       Date:  2012-10-23       Impact factor: 3.046

6.  Should cognitive impairment be included in the diagnostic criteria for schizophrenia?

Authors:  Richard S E Keefe
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

Review 7.  Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond.

Authors:  Emre Bora; Murat Yücel; Christos Pantelis
Journal:  Schizophr Bull       Date:  2009-09-23       Impact factor: 9.306

8.  Associations between psychotic-like symptoms and inattention/hyperactivity symptoms.

Authors:  Tuula Marketta Hurtig; Anja Taanila; Juha Veijola; Hanna Ebeling; Pirjo Mäki; Jouko Miettunen; Marika Kaakinen; Matti Joukamaa; Sebastian Therman; Markus Heinimaa; Marjo-Riitta Järvelin; Irma Moilanen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-11-12       Impact factor: 4.328

Review 9.  How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association.

Authors:  Amélie M Achim; Michel Maziade; Eric Raymond; David Olivier; Chantal Mérette; Marc-André Roy
Journal:  Schizophr Bull       Date:  2009-12-03       Impact factor: 9.306

10.  Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability.

Authors:  Katherine E Burdick; Pamela DeRosse; John M Kane; Todd Lencz; Anil K Malhotra
Journal:  Am J Psychiatry       Date:  2010-01-15       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.